Utama › Kanser Kulit › Texas
Kajian klinikal Kanser Kulit di Texas
6 kajian untuk Kanser Kulit sedang mencari peserta di lokasi di Texas.
Bandar di Texas
Teks kajian rasmi (Bahasa Inggeris)
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
- The University of Texas at Austin Dell Medical School Ascension Medical Group, Austin
- U.S. Dermatology Partners, Cedar Park
- Reveal Research Institute, Dallas
- dan 4 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT06585410Safety and Efficacy of OBX-115 in Advanced Solid Tumors
- M.D. Anderson Cancer Center (Melanoma/NSCLC), Houston
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Jul 2026 · NCT06060613Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- JPS Health Network, Forth Worth
- Baylor Scott and White Biorepository, Temple
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jun 2026 · NCT07327489Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
- The University of Texas MD Anderson Cancer Center, Houston
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Apr 2026 · NCT06947928A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
- MD Anderson Cancer Center, Houston
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Apr 2026 · NCT06362369SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Dallas
- Massive Bio SYNERGY-AI site, Houston
- Massive Bio SYNERGY-AI site, Temple
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.